| US 7,572,589 B2 | ||
| Diagnosis and treatment of infectious diseases through indel-differentiated proteins | ||
| Neil E. Reiner, Vancouver (Canada); Artem Tcherkassov, Vancouver (Canada); and Devki Nandan, Vancouver (Canada) | ||
| Assigned to The University of British Columbia, Vancouver, British Columbia (Canada) | ||
| Appl. No. 10/494,175 PCT Filed Nov. 01, 2002, PCT No. PCT/CA02/01689 § 371(c)(1), (2), (4) Date Oct. 28, 2004, PCT Pub. No. WO03/037926, PCT Pub. Date May 08, 2003. |
||
| Claims priority of provisional application 60/349371, filed on Jan. 22, 2002. | ||
| Claims priority of provisional application 60/349339, filed on Jan. 22, 2002. | ||
| Claims priority of provisional application 60/393385, filed on Jul. 05, 2002. | ||
| Claims priority of application No. 2360987 (CA), filed on Nov. 01, 2001. | ||
| Prior Publication US 2005/0095247 A1, May 05, 2005 | ||
| Int. Cl. G01N 33/53 (2006.01); A61K 39/395 (2006.01); C07K 17/00 (2006.01) | ||
| U.S. Cl. 435—7.1 [424/145.1; 424/146.1; 530/388.6; 530/391.1] | 21 Claims |
| 1. A method for testing a compound for specific binding to a pathogen protein, comprising:
a) selecting a protein conserved between a pathogen and a host to the pathogen
b) identifying an indel in the conserved protein, wherein the pathogen protein has an indel not present in the host protein
and
c) contacting a compound to be tested with each of the pathogen protein and the host protein to compare binding; wherein binding
of the compound to the pathogen protein and the absence or reduced binding of the compound to the host protein is indicative
of the compound being capable of said specific binding to the pathogen protein.
|